Novel targets for development of drugs for treating schizophrenia: Focus on glycine, D-serine and nitric oxide

Klinik Psikofarmakoloji Bulteni

Volumn 23, Issue 2, 2013, Pages 129-137

  Dhami, Kamaldeep ^a   MacKay, Marnie ^a   Maia de Oliveira, Joao Paulo ^b   Hallak, Jaime ^a,b   Todd, Kathryn ^a   Baker, Glen ^a,b   Dursun, Serdar ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

D serine; Dopamine; Glutamate; Glycine reuptake; Nitric oxide; Schizophrenia; Sodium nitroprusside

Indexed keywords

BITOPERTIN; DEXTRO SERINE; GLYCINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; OLANZAPINE; PLACEBO; RISPERIDONE; SILDENAFIL;

BRIEF PSYCHIATRIC RATING SCALE; DRUG MEGADOSE; HUMAN; NEUROTRANSMISSION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA;

EID: 84879715013     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.5455/bcp.20130629042437     Document Type: Review

References (88)

1. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963;20:140-4.
2. van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 1966;160(2):492-4.
3. Baumeister AA, Francis JL. Historical development of the dopamine hypothesis of schizophrenia. J Hist Neurosci 2002;11(3):265-77.
4. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148(11):1474-86.
5. Seeman P. All psychotic roads lead to increased dopamine D2High receptors: a perspective. Clin Schizophr Relat Psychoses 2008;1:351-5.
6. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathyway. Schizophr Bull 2009;35(3):549-62.
7. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(7):1159-72.
8. Wassef A, Baker J, Kochan LD. GABA and schizophrenia: a review of basic science and clinical studies. J Clin Psychopharmacol 2003; 23(6):601-40.
9. Scarr E, Gibbons AS, Neo J, Udawela M, Dean B. Cholinergic connectivity: it's implications for psychiatric disorders. Front Cell Neurosci 2013;7:55.
10. MacKenzie EM, Odontiadis J, Le Mellédo JM, Prior TI, Baker GB. The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders. Cell Mol Neurobiol 2007;27(5):541-74.
11. Marx CE, Bradford DW, Hamer RM, Naylor JC, Allen TB, Lieberman JA, et al. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience 2011;191:78-90.
12. Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann NY Acad 2003;1003:318-27.
13. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158(9):1367-77.
14. Gordon JA. Testing the glutamate hypothesis of schizophrenia. Nat Neurosci 2010:13(1):2-4.
15. Krystal JH, Perry EB Jr, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 2005;62(9):985-94.
16. Bernstein HG, Keilhoff G, Steiner J, Dobrowolny H, Bogerts B. Nitric oxide and schizophrenia: Present knowledge and emerging concepts of therapy. CNS Neurol Disord Drug Targets 2011;10(7):792-807.
17. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51(3):199-214.
18. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52(12):998-1007.
19. Seillier A, Giuffrida A. Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. Behav Brain Res 2009; 204(2):410-5.
20. Lynch DR, Guttmann RP. Excitotoxicity: perspectives based on N-methyl-D-aspartate receptor subtypes. J Pharmacol Exp Ther 2002; 300(3):717-23.
21. Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 2011; 25(10):859-85.
22. Hashimoto K, MalchowB, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 2013 (in press).
23. Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt DC, Heresco-Levy U. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry 2005; 162(9):1738-40.
24. Martina M, Gorfinkel Y, Halman S, Lowe JA, Periyalwar P, Schmidt CJ, et al. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J Physiol 2004; 557(Pt 2):489-500.
25. Song W, Chattipakorn SC, McMahon LL. Glycine-gated chloride channels depress synaptic transmission in rat hippocampus. J Neurophysiol 2006; 95(4):2366-79.
26. Nikiforuk A, Kos T, Rafa D, Behl B, Bespalov A, Popik P. Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner. Neuropharmacology 2011; 61(1-2):262-7.
27. Hashimoto K. Glycine transporter-1: a new potential therapeutic target for schizophrenia. Curr Pharm Design 2011; 17(2):112-20.
28. Zafra F, Gimenez C. Glycine transporters and synaptic function. IUBMB Life 2008; 60(12):810-7.
29. Javitt DC, Sershen H, Hashim A, Lajtha A. Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 1997; 17(3):202-4.
30. Harsing LG Jr, Solyom S, Salamon C. The role of glycineB binding site and glycine transporter (GlyT1) in the regulation of [3H]GABA and [3H]glycine release in the rat brain. Neurochem Res 2001; 26(8-9):915-23.
31. Yang CR, Svensson KA. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia. Pharmacol Ther 2008; 120(3):317-32.
32. Chen L, Muhlhauser M, Yang CR. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol 2003; 89(2):691-703.
33. Lipina T, Labrie V, Weiner I, Roder J. Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology 2005; 179(1):54-67.
34. Karasawa J, Hashimoto K, Chaki S. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res 2008; 186(1):78-83.
35. Javitt DC, Balla A, Burch S, Suckow R, Xie S, Sershen H. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycinesite agonists. Neuropsychopharmacology 2004; 29(2):300-7.
36. Bennett S, Gronier B. Modulation of striatal dopamine release in vitro by agonists of the glycineB site of NMDA receptors; interaction with antipsychotics. Eur J Pharmacol 2005; 527(1-3):52-9.
37. Harsing LG, Zsilla G, Matyus P, Nagy KM, Marko B, Gyarmati Z, et al. Interactions between glycine transporter type 1 (GlyT-1) and some inhibitor molecules-glycine transporter type 1 and its inhibitors (review). Acta Physiol Hung 2012; 99(1):1-17.
38. Chue P. Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1). Curr Pharm Des 2013; 19(7):1311-20.
39. Black MD, Varty GB, Arad M, Barak S, De Levie A, Boulay D, et al. Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology 2009; 202(1-3):385-96.
40. Depoortere R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 2005; 30(11):1963-85.
41. Pinard E, Alanine A, Alberati D, Bender M, Borroni E, Bourdeaux P, et al. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl] [5-methanesulfonyl-2-(S)-2,2,2-trifluoro-1-methylethoxy) phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J Med Chem 2010; 53(12):4603-14.
42. Harada K, Nakato K, Yarimizu J, Yamazaki M, Morita M, Takahashi S, et al. A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazol e), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. Eur J Pharmacol 2012; 685(1-3):59-69.
43. Roberts BM, Shaffer CL, Seymour PA, Schmidt CJ, Williams GV, Castner SA. Glycine transporter inhibition reverses ketamine-induced working memory deficits. Neuroreport 2010; 21(5):390-4.
44. Nagy K, Marko B, Zsilla G, Matyus P, Pallagi K, Szabo G, et al. Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone. Neurochem Res 2010; 35(12):2096-106.
45. Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006; 60(6):645-9.
46. Jardemark K, Marcus MM, Malmerfelt A, Shahid M, Svensson TH. Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission. Psychopharmacology 2012; 221(1):115-31.
47. Choi YK, Gardner MP, Tarazi FI. Effects of risperidone on glutamate receptor subtypes in developing rat brain. Eur Neuropsychopharmacol 2009; 19(2):77-84.
48. Roenker NL, Gudelsky G, Ahlbrand R, Bronson SL, Kern JR, Waterman H, et al. Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801. Neurosci Lett 2011; 500(3):167-71.
49. Martina M, Krasteniakov NV, Bergeron R. D-Serine differently modulates NMDA receptor function in rat CA1 hippocampal pyramidal cells and interneurons. J Physiol 2003; 548(Pt 2):411-23.
50. Hashimoto K, Fujita Y, Ishima T, Chaki S, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine. Eur Neuropsychopharmacol 2008; 18(6):414-21.
51. Kanahara N, Shimizu E, Ohgake S, Fujita Y, Kohno M, Hashimoto T, et al. Glycine and D-serine, but not D-cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. Psychopharmacology 2008; 198(3):363-74.
52. Kretschmer BD, Koch M. Role of the strychnineinsensitive glycine binding site in the nucleus accumbens and anterodorsal striatum in sensorimotor gating: a behavioral and microdialysis study. Psychopharmacology 1997;130(2):131-8.
53. Balu DT, Li Y, Puhl MD, Benneyworth MA, Basu AC, Takagi S, et al. Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc Natl Acad Sci U S A 2013 (in press).
54. Labrie V, Fukumura R, Rastogi A, Fick LJ, Wang W, Boutros PC, et al. Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum Mol Genet 2009; 18(17):3227-43.
55. Horio M, Kohno M, Fujita Y, Ishima T, Inoue R, Mori H, et al. Levels of D-serine in the brain and peripheral organs of serine racemase (Srr) knock-out mice. Neurochem Int 2011; 59(6):853-9.
56. Nunes EA, MacKenzie EM, Rossolatos D, Perez-Parada J, Baker GB, Dursun SM. D-Serine and schizophrenia: an update. Expert Rev Neurother 2012; 12(7):801-12.
57. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 1999; 45(1):17-25.
58. Sacchi S, Rosini E, Pollegioni L, Molla G. D-amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy. Curr Pharm Des 2013; 19(14):2499-511.
59. Adage T, Trillat AC, Quattropani A, Perrin D, Cavarec L, Shaw J, et al. In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur Neuropsychopharmacol 2008; 18(3):200-14.
60. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44(11):1081-9.
61. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005; 57(6):577-85.
62. Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 2010; 13(4):451-60.
63. Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res 2010; 121(1-3):125-30.
64. Bredt DS, Snyder SH. Nitric oxide, a novel neuronal messenger. Neuron 1992; 8(1):3-11.
65. Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Annu Rev Physiol 1995;57:683-706.
66. Maia-de-Oliveira JP, Trzesniak C, Oliveira IR, Kempton MJ, Rezende TM, Baker GB, et al. Nitric oxide plasma/serum levels in patients with schizophrenia; A systematic review and meta-analysis. Rev Bras Psiquiatr 2012; 34(Suppl. 2): S149-S55.
67. Pogun S, Kuhar MJ. Regulation of neurotransmitter reuptake by nitric oxide. Ann N Y Acad Sci 1994;738:305-15.
68. Lonart G, Wang J, Johnson KM. Nitric oxide induces neurotransmitter release from hippocampal slices. Eur J Pharmacol 1992; 220(2-3):271-2.
69. Prast H, Philippu A. Nitric oxide as modulator of neuronal function. Prog in Neurobiol 2001; 64(1):51-68.
70. Kiss JP, Vizi ES. Nitric oxide: A novel link between synaptic and nonsynaptic transmission. Trends in Neurosci 2001; 24(4):211-5.
71. Zukin SR, Zukin RS. Specific [3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci U S A 1979;76(10):5372-6.
72. Bujas-Bobanovic M, Bird DC, Robertson HA, Dursun SM. Blockade of phencyclidine-induced effects by a nitric oxide donor. Br J Pharmacol 2000; 130(5):1005-12.
73. Bujas-Bobanovic M, Robertson HA, Dursun SM. Effects of nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester on phencyclidine-induced effects in rats. Eur J Pharmacol 2000; 409(1):57-65.
74. Pitsikas N. The nitric oxide (NO) donor molsidomine antagonizes scopolamine and L-NAME-induced performance deficits in a spatial memory task in the rat. Beh Brain Res 2009; 200(1):160-4.
75. Pitsikas N, Zisopoulou S, Sakellaridis N. Nitric oxide donor molsidomine attenuates psychotomimetic effects of the NMDA receptor antagonist MK-801. J Neurosci Res 2006; 84(2):299-305.
76. Noda Y, Yamada K, Furukawa H, Nabeshima T. Involvement of nitric oxide in phencyclidine-induced hyperlocomotion in mice. Eur J Pharmacol 1995; 286(3):291-7.
77. Noda Y, Yamada K, Komori Y, Sugihara H, Furukawa H, Nabeshima T. Role of nitric oxide in the development of tolerance and sensitization to behavioural effects of phencyclidine in mice. Br J Pharmacol 1996; 117(7):1579-85.
78. Bird DC, Bujas-Bobanovic M, Robertson HA, Dursun SM. Lack of phencyclidine-induced effects in mice with reduced neuronal nitric oxide synthase. Psychopharmacology 2001; 155(3):299-309.
79. Nakano Y, Yoshimura R, Nakano H. Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study. Hum Psychopharmacol 2010; 25(2):139-44.
80. Lee BH, Kim YK. Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls. Schizophr Research 2008; 104(1-3):36-43.
81. Suzuki E, Nakaki T, Nakamura M, Miyaoka H. Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia. J Psychiatry Neurosci 2003; 28(4):288-92.
82. Ramirez J, Garnica R, Boll MC, Montes S, Rios C. Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: A pilot study. Schiz Res 2004; 68(2-3):357-61.
83. Gattaz WF, Cramer H, Beckmann H. Low CSF concentrations of cyclic GMP in schizophrenia. Br J Psychiatry 1983;142:288-91.
84. Gattaz WF, Cramer H, Beckmann H. Haloperidol increase the cerebrospinal fluid concentrations of cyclic GMP in schizophrenic patients. Biol Psychiatry 1984; 19(8):1229-35.
85. Ebstein RP, Biederman J, Rimon R, Zohar J, Belmaker RH. Cyclic GMP in the CSF of patients with schizophrenia before and after neuroleptic treatment. Psychopharmacology 1976; 51(1):71-4.
86. Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011; 473(7346):221-5.
87. Akhondzadeh S, Ghayyoumi R, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, et al. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: A double-blind randomized placebo-controlled trial. Psychopharmacology 2011; 213(4):809-15.
88. Hallak JE, Maia-de-Oliveira JP, Abrao J, Evora PR, Zuardi AW, Crippa JA, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside. JAMA Psychiatry 2013; 8:1-9.